Table 1 Patients clinical characteristics and survival
From: Cytoreduction and HIPEC in the treatment of “unconventional” secondary peritoneal carcinomatosis
PT | Age | Sex | Primary T | HIPEC | PCI | CC | FU | Surv |
|---|---|---|---|---|---|---|---|---|
1 | 72 | M | Sarcoma | OXALa | 20 | 1 | DODc | 12 |
2 | 77 | F | Sarcoma | OXALa | 16 | 0 | AWDd | 11 |
3 | 61 | M | Sarcoma | OXALa | 14 | 1 | AWDd | 9 |
4 | 68 | F | Small bowel | CDDPb | 26 | 0 | ADFe | 23 |
5 | 51 | M | Small bowel | CDDPb | 15 | 0 | AWDd | 23 |
6 | 59 | M | Small bowel | CDDPb | 20 | 1 | AWDd | 8 |
7 | 46 | F | Small bowel | CDDPb | 7 | 0 | AWDd | 3 |
8 | 67 | M | Pancreas | OXALc | 23 | 1 | ADFe | 5 |
9 | 67 | M | Pancreas | OXALc | 22 | 2 | AWDd | 4 |
10 | 74 | F | Pancreas | OXALc | 3 | 0 | ADFe | 8 |
11 | 70 | F | GISTf | CDDPb | 6 | 0 | ADFe | 34 |
12 | 53 | F | GISTf | CDDPb | 12 | 0 | ADFe | 108 |
13 | 73 | M | GISTf | CDDPb | 20 | 0 | DODc | 38 |
14 | 58 | F | Breast IDCg | CDDPb | 15 | 0 | ADFe | 128 |
15 | 54 | F | Breast ILCh | CDDPb | 22 | 1 | ADFe | 74 |
16 | 55 | F | Breast ILCh | CDDPb | 22 | 2 | DODc | 56 |
17 | 77 | F | Breast IDCg | CDDPb | 24 | 1 | ADFe | 45 |
18 | 53 | F | Breast IDCg | CDDPb | 18 | 0 | ADFe | 13 |
19 | 60 | M | Bladder | CDDPb | 19 | 2 | DODc | 9 |
20 | 68 | F | Type II UPSCi | CDDPb | 5 | 0 | DODc | 46 |
21 | 56 | F | Type II UPSCi | CDDPb | 6 | 0 | DODc | 24 |
22 | 64 | F | Type II UPSCi | CDDPb | 23 | 0 | AWDd | 12 |
23 | 58 | F | Type II UPSCi | CDDPb | 17 | 0 | AWDd | 52 |
24 | 61 | F | Type II UPSCi | CDDPb | 9 | 0 | ADFe | 95 |
25 | 67 | F | Type II UPSCi | CDDPb | 30 | 1 | DODc | 15 |
26 | 59 | F | Type II UPSCi | CDDPb | 29 | 1 | DODc | 15 |
27 | 65 | F | Type II UPSCi | CDDPb | 19 | 0 | DODc | 12 |
28 | 51 | M | Lung | CDDPb | 19 | 0 | DODc | 7 |